Wilma Uyterlinde

A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients

Cary Oberije, Dirk De Ruysscher, Ruud Houben et al. · International Journal of Radiation Oncology*Biology*Physics · 2015 · 106 citations · Full text

Medicine, Biostatistics, Oncology +17

89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer

Iris C. Kok, J.S. Hooiveld, Pim P. van de Donk et al. · Annals of Oncology · 2021 · 95 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Long-term follow-up of patients with locally advanced non-small cell lung cancer receiving concurrent hypofractionated chemoradiotherapy with or without cetuximab

Iris Walraven, Michel M. van den Heuvel, Judi van Diessen et al. · Radiotherapy and Oncology · 2016 · 70 citations · Full text

Medicine, Oncology, Radiation Oncology +14

Acute Esophagus Toxicity in Lung Cancer Patients After Intensity Modulated Radiation Therapy and Concurrent Chemotherapy

Margriet Kwint, Wilma Uyterlinde, Jasper Nijkamp et al. · International Journal of Radiation Oncology*Biology*Physics · 2012 · 65 citations

Medicine, Oncology, Radiation Oncology +17

Severe late esophagus toxicity in NSCLC patients treated with IMRT and concurrent chemotherapy

Chun Chen, Wilma Uyterlinde, Jan‐Jakob Sonke et al. · Radiotherapy and Oncology · 2013 · 55 citations

Medicine, Oncology, Radiation Oncology +13